Zacks Investment Research downgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a buy rating to a hold rating in a report published on Monday.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
A number of other research analysts have also recently commented on the company. BidaskClub cut Assembly Biosciences from a buy rating to a hold rating in a research note on Saturday, January 6th. B. Riley assumed coverage on Assembly Biosciences in a research report on Friday, January 5th. They set a neutral rating and a $35.00 price objective on the stock. ValuEngine lowered Assembly Biosciences from a hold rating to a sell rating in a research report on Thursday, December 7th. Jefferies Group assumed coverage on Assembly Biosciences in a research report on Wednesday, November 8th. They set a buy rating and a $50.00 price objective on the stock. Finally, Chardan Capital reaffirmed a buy rating on shares of Assembly Biosciences in a research report on Sunday, September 17th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of Hold and an average price target of $39.25.
Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.17. equities research analysts predict that Assembly Biosciences will post -3.22 EPS for the current year.
In other news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $49.37, for a total transaction of $49,370.00. Following the sale, the director now owns 20,465 shares of the company’s stock, valued at $1,010,357.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 3,000 shares of company stock worth $123,960 in the last ninety days. Corporate insiders own 19.60% of the company’s stock.
A number of large investors have recently bought and sold shares of ASMB. State Street Corp purchased a new position in Assembly Biosciences in the second quarter valued at $4,234,000. JPMorgan Chase & Co. purchased a new position in Assembly Biosciences in the second quarter valued at $3,426,000. Valeo Financial Advisors LLC purchased a new position in Assembly Biosciences in the third quarter valued at $4,963,000. Northern Trust Corp increased its holdings in Assembly Biosciences by 221.2% in the second quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 134,513 shares during the last quarter. Finally, AXA purchased a new position in Assembly Biosciences in the second quarter valued at $2,477,000. 61.41% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3146056/assembly-biosciences-asmb-downgraded-by-zacks-investment-research-to-hold.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.